Full Course Description


Psychedelic-Assisted Therapy In-depth: In-session demonstrations and real-world insight into MDMA & more

Program Information

Objectives

  1. Analyze the recent history and results of the clinical trials of MDMA-assisted therapy (MDMA-AT) for PTSD.
  2. Catalogue the side effects of MDMA, and possible risks and contraindications of psychedelic-assisted therapy.
  3. Design a therapeutic approach based on the MAPS Therapist Manual and the approach used in MDMA-AT clinical trials.
  4. Debate some possible mechanisms for the therapeutic effects of psychedelics in conjunction with psychotherapy.
  5. Evaluate at least 4 psychedelics that are currently under investigation in clinical trials, and catalogue some conditions they are being studied for.

Copyright : 04/08/2022

Psychedelics & Racial Justice

Psychedelics have been studied for the treatment of PTSD, depression, end-of-life anxiety, OCD, addictions, and a number of other mental health conditions. However, research studies of psychedelic psychotherapies have largely excluded people of colour, leaving important questions unaddressed for these populations.   

Dr. Williams will review relevant research, documenting exclusion based on the international literature. She will discuss ethnic minority mental health and how psychedelic therapies may help or hinder healing for people of colour.  Also discussed are next steps in ensuring that access to culturally-informed care is prioritized as several psychedelics move into late phase trials and expanded access, including the importance of culturally-informed approaches and training focused on therapy providers of colour. 

Program Information

Objectives

  1. Analyze how discrimination affects the mental health of people of colour.
  2. Theorize how race, ethnicity, and culture are important in psychedelic-assisted psychotherapy.
  3. Catalogue new research pertaining to psychedelics and racialized populations.

Copyright : 28/07/2022

Psychedelics in Modern Healing

Today there’s growing interest in the use of psychedelic substances, once considered therapeutically off-limits, in the clinical treatment of PTSD, depression, addictions, and a range of other conditions.

The principles on which these healing pathways are based have been shown to be validated by psychoneuroimmunology and interpersonal neurobiology.

This workshop recording will look at the distinctive experiences of both clients and therapists that psychedelics can facilitate.

Program Information

Objectives

  1. Appraise the differences among various psychedelic substances and their potential uses in a therapeutic setting. 
  2. Investigate the process of introducing and preparing for a psychedelic-based session with clients. 
  3. Assess how to integrate what has been experienced and learned in a psychedelic journey after the session. 

Copyright : 23/03/2019

Psychedelic Harm Reduction and Integration in Clinical Practice

What do you do when a client lets you know they are going to use psychedelics on their own, as part of a ceremony, spiritual practice or because they’ve heard it can help them? Is there anything you can do to help reduce harm? And what about micro-dosing, which is gaining popularity?

Psychedelic Harm Reduction and Integration (PHRI) is a transdiagnostic and transtheoretical approach that YOU as a mental health professional can take to having conversations with people who have taken psychedelics in clinical or non-clinical settings, or who are seeking help at any stage of psychedelic use. This recording will cover the core concepts of PHRI and its applications, including discussions about microdosing, responding to requests for referrals to non-licensed providers, and working with difficult experiences. 

Program Information

Objectives

  1. Differentiate Psychedelic Harm Reduction and Integration from Psychedelic-assisted Therapy.  
  2. Determine ways to intervene with clients who are using or micro-dosing psychedelics.
  3. Assess four theoretical pillars of the Psychedelic Harm Reduction and Integration model.  
  4. Integrate Psychedelic Harm Reduction and Integration into the larger picture of psychedelic-assisted therapies.

Copyright : 27/07/2022